This medicine is authorised for use in the European Union.


Cablivi is a medicine for use in adults and children from 12 years of age weighing at least 40 kg and who have an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a blood clotting disorder. During an episode of aTTP, blood clots form in small blood vessels and the patient has a low count of platelets (components that help the blood to clot).

Cablivi is used together with plasma exchange (a procedure that removes certain antibodies from the blood) and treatments to reduce the activity of the immune system (the body’s defences).

Cablivi contains the active substance caplacizumab.

aTTP is rare, and Cablivi was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 30 April 2009. Further information on the orphan designation:EU/3/09/629.

This EPAR was last updated on 15/05/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Purpura, Thrombotic Thrombocytopenic
Anatomical therapeutic chemical (ATC) code

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Ablynx NV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Technologiepark 21
9052 Zwijnaarde

Product information

17/04/2023 Cablivi - EMEA/H/C/004426 - R/0042

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.

Assessment history

Related content

How useful was this page?

Add your rating
2 ratings
1 rating
2 ratings